Abstract
Introduction
Malignant melanoma is a public health challenge with a rising incidence rate and estimates of 47,700 new cases to be diagnosed annually (1) (2) (3) . The significant mortality of this cancer is associated with its high cellular proliferation rate and the early occurrence of metastases. Because early detection of the melanoma and its associated metastases considerably improves management and prognosis of the disease, there has been intense interest in the search for melanoma-specific diagnostic imaging probes and therapeutic agents (4, 5 (6) . Other prospective clinical studies have also shown the utility of whole-body [ 18 F]FDG PET imaging in stage II to IV melanoma with sensitivity and specificity of 94.2% and 83.3%, respectively, for lesions in the soft tissue, lymph nodes, and liver (7); false-positives are due to the accumulation of [ 18 F]FDG in surgical wounds, pneumonia, and other etiologies including infection/ inflammation (6) (7) (8) (9) .
A number of radiolabeled, single-photon emission computed tomography (SPECT) metabolic tracers, peptides, and monoclonal antibodies have also been investigated for melanoma detection, staging, and follow-up (4, 5) . Among these SPECT agents, the most promising are the radioiodinated benzamides (10) (11) (12) (13) (14) . Although the nature of the affinity of iodobenzamides for melanoma is not clearly understood, it has been shown that radiolabeled iodobenzamides possess a considerable in vivo affinity for melanotic melanoma lesions compared with amelanotic lesions (10) 123 I]BZA at 1 hour postinjection and a 4-fold higher ratio at 4 hours in the C57BL6 mouse model (12, 13) . Preliminary scintigraphic studies in patients with melanoma metastases have confirmed the efficacy of this compound (12) . More recently, a single-center clinical trial in 25 patients using another radioiodinated iodobenzamide derivative, N-(2-diethylaminoethyl)-2- Fig. 1 ), showed 100% sensitivity, 95% specificity, a positive predictive value of 86%, and a negative predictive value of 100% on a per patient basis (14) .
Whereas Tc generator. It has a high photon flux and emits 140 keV g-photons with ideal characteristics for SPECT imaging, making it very cost-effective and the radiolabel of choice for routine clinical imaging. Technetium complexes that contain structural elements of the benzamides have been explored, including technetium-99m-labeled nitridotechnetium-bis(aminethiol)benzamide (TcN-BAT-BZA) and oxotechnetium-bis(aminethiol)benzamide (TcO-Cf; Fig. 1) ; the latter has limited tumor uptake [<1.6% injected dose/gram (% ID/g) at 60 minutes postinjection] in the B16 mouse melanoma model (15) (16) (17) .
Our attempts to design technetium-based, small molecules that possess structural elements of the benzamides are based on the strategy of replacing the aromatic moiety in the benzamide structure with a chelated metal-oxo core linked to the tertiary amine substituent. Applying this strategy via a ''3 + 1'' tridentate/ monodentate chelating approach has produced 99m TcO(SNS)(S-C 2 -NEt 2 ) ( Fig. 1 ) and 99m TcO(SNS)(S-C 2 -NBu 2 ) complexes with significantly higher tumor accumulation (3.1% and 5% ID/g, respectively, at 60 minutes postinjection; ref. 18 ) compared with the benzamide-containing technetium complex TcO-Cf. Because the use of these ''3 + 1'' complexes as imaging agents could be hampered by their known tendency to form transchelation products with glutathione in vivo (19), we have modified the strategy and have synthesized a focused library of complexes based on the tetradentate chelate, amine-amide-dithiol (AADT), containing only tertiary amine substituents [AADT-CH 2 -[CH 2 ] n -NR 2 (n = 1, 2; R = Et, n-Bu, piperidino, morpholino); refs. [20] [21] [22] ; most of these complexes display considerable affinity for melanoma both in vitro and in vivo, with the [ 99m TcOAADT]-(CH 2 ) 2 -NEt 2 derivative ( 99m Tc-1) having a high in vivo melanoma uptake of 7.6% ID/g (melanoma/nontarget tissue = 9.5) at 1 hour postinjection in the s.c. C57BL6/B16F0 mouse model (20) . Described herein is a study of this small, neutral complex 99m Tc-1 ( Fig. 1 ) in a more realistic lung metastatic melanoma model with a temporal tumor growth pattern that illustrates the potential use of 99m Tc-1 as a small-molecule SPECT imaging probe for the in vivo diagnosis of metastatic sites in malignant melanoma.
Materials and Methods
General. All chemicals and reagents were purchased from commercial sources (Sigma-Aldrich, St. Louis, MO; Gibco Life Technologies, Gaithersburg, MD). Technetium-99m pertechnetate was obtained via a 99 Mo99m Tc generator (DuPont NEN, Bilricca, MA). High-performance liquid chromatography (HPLC) purification was done on a Waters Millennium Chromatography System equipped with a 996 UV-Vis diode-array detector attached in series to a g-detector consisting of a shielded photomultiplier powered by a Canberra voltage amplifier and connected to a ratemeter. For the analytic and preparative HPLC purification of the radiolabeled complex, a reverse-phase C8 column equipped with a C18 guard was eluted with methanol (solvent A) and 5 mmol/L PBS, pH 7.4 (solvent B, Gibco Life Technologies) using a 30-minute linear gradient from 15:85 (A/B) to 90:10 (A/B) at a 1.0 mL/min flow rate.
Synthesis of [ 99m TcOAADT]-(CH 2 ) 2 -NEt 2 . The AADT-(CH 2 ) 2 -NEt 2 ligand and its technetium-99m complex were synthesized following procedures described previously (20) . Briefly, 5.0 mg trityl-protected ligand was dissolved in 10 mL trifluoroacetic acid (TFA), and the resulting yellowcolored solution was titrated with triethylsilylhydride until it turned colorless. TFA was completely evaporated from the colorless solution on a rotary evaporator followed by additional drying via high vacuum. The dry residue was later redissolved in argon-saturated methanol and distributed into 10 vials that were dried and kept under vacuum for later preparation of the technetium-99m-labeled compound. Tc-glucoheptonate solution (0.3 mL), and the reaction was heated at 75jC for 25 minutes in a water bath. HPLC analysis of the reaction mixture typically indicated >90% radiochemical yield of the 99m Tc-1 complex (Fig. 2) . In addition, coinjection of the structurally characterized rhenium complex (20) with the analogous 99m Tc-1 complex resulted in coelution of the radioactive species with the corresponding UV-active rhenium complex. All in vitro and in vivo experiments were conducted with the 99m Tc-1 complex isolated via preparative HPLC. The solution was subsequently evaporated to complete dryness and the complex reconstituted in sterile distilled water to the required radioactivity concentration.
In vitro studies with murine B16F10 melanoma cells. B16F10 cells (2 Â 10 6 ) from the American Type Culture Collection (Manassas, VA) were plated and grown in three T-175 flasks in 14 mL DMEM (pH 7.4; Gibco Life Technologies) containing 4,500 mg/L D-glucose, L-glutamine, and pyridoxine hydrochloride, 110 mg/L sodium pyruvate, 10% fetal bovine serum, 0.2% gentamicin, and 0.5% penicillin-streptomycin solution.
At the time of the cell uptake assay, all cells were harvested from the culture flasks by trypsinization with 1 mL trypsin-EDTA solution (0.25% trypsin, 1 mmol/L EDTAÁ4Na; Gibco Life Technologies). After being washed twice with 12 mL cold PBS (Gibco Life Technologies), the cells were counted and resuspended in Ca 99m Tc-1 in a total volume of 500 AL S-MEM with intermittent agitation. At appropriate time intervals, the tubes were vortexed and triplicate samples of 15 AL were layered in individual 400-AL Eppendorf microcentrifuge tubes containing 350 AL cold calf serum. After centrifugation at 12,000 rpm for 1 minute, the tubes were frozen in a dry ice-acetone bath and, while still frozen, cut into two sections (a bottom section containing the cell pellet and an upper section with the supernatant) that were placed in individual counting tubes. Both fractions were counted for radioactivity in a g-counter (WALLAC, 1480 WIZARD 3). The percentage of 99m Tc-1 uptake was calculated as % cell uptake = 100
In vivo studies in murine melanoma C57BL6/B16F10 mouse models. Pulmonary melanoma metastases in C57BL6 mice resulting from the i.v. inoculation of B16F10 melanoma cells were produced using two independent groups of C57BL6 male mice as previously described (24) (25) (26) . One group was given 4 Â 10 5 viable B16F10 melanoma cells (0.1 mL) via lateral tail vein injection. On 11, 14, and 17 days after tumor cell inoculation, these mice received an i.v. injection of Tc-1 (25-40 ACi in 0.1 mL). At 2 and 3 hours after injection of 99m Tc-1, the mice were weighed and sacrificed. Various organs and tumor-bearing lungs were harvested and placed in preweighed tubes, with the excised lungs, liver, spleen, and brain collected in tubes containing 15% formalin buffer. Radioactivity in the various organs was determined in a g-counter along with a known standard of technetium-99m, and subsequently the tissues/ organs were weighed. The excised lung tissues were then prepared for ex vivo radiophosphor imaging (see below). In the second group of mice, similar biodistribution studies were done 14 days after i.v. injection in
organ weights, the tubes were stored for radioactivity decay. Subsequently the tissues/organs were processed for histopathologic examination. In vivo biodistribution studies with 99m Tc-1 were also done in normal (control) mice that did not receive an i.v. tumor cell inoculation.
Subcutaneous tumors were created using 2.5 Â 10 5 B16F10 cells (0.1 mL) transplanted s.c. on the left hind flank of C57BL6 male mice. After 10 to 14 days, the animals developed palpable tumor nodules 0.5 to 1.0 cm in diameter. The biodistribution studies were carried out in these mice at 2, 3, and 6 hours after tail vein injection of 25 to 40 ACi (0.1 mL)
99m Tc-1. The organs and tumors were harvested and counted in a g-counter along with technetium-99m standards of the injected dose. The results are expressed as % ID/g.
All animal experiments were done in compliance with the Principles of Laboratory Animal Care (NIH publication no. 85-23, revised 1985) and under approved institutional animal protocols.
Radiophosphor imaging. Excised lung tissue collected from tumorbearing mice was placed in preweighed tubes containing 15% formalin buffer solution and subjected to ex vivo radiophosphor imaging. The formalin-fixed lung tissues were blotted dry on tissue paper and placed on a clean microscope slide and photographed with a digital camera. The slides were then placed in a phosphor imaging cassette (Molecular Dynamics, Inc., Sunnyvale, CA). In the closed imaging cassette, the lung tissues were compressed to a thickness of 1 to 2 mm. The imaging plates were exposed overnight to the lung tissues to accumulate counts. These counts were then processed on a Molecular Dynamics Phosphor Imager (Storm 860 Scanner, Scanner Control Version 4.1, Molecular Dynamics) to obtain the radiophosphor images. Image analysis was carried out with the software program ImageQuant 1.2 (Molecular Dynamics).
Histology. The excised lung, liver, spleen, and brain tissues collected in 15% formalin buffer were processed for histopathologic studies after the complete decay of radioactivity. The tissue was embedded in paraffin and 5-Am-thin sections were cut on a microtome and stained with H&E. Slides of all the sample tissues were examined under light microscopy to determine the presence, extent, and size of melanoma metastases. Statistical methods. Statistical analysis was done using Student's t test for unpaired data. A 95% confidence level was chosen to determine the significance between days, with P < 0.05 being significantly different.
Results and Discussion
Small technetium-labeled molecules based on the structural elements of the iodobenzamides currently in clinical trials for melanoma detection (11, 12, 14) have also been identified as possessing high in vivo melanoma accumulation. [ 99m Tc]oxotechnetium(V) complexes of tetradentate N 2 S 2 (AADT) chelates containing only tertiary amine substituents have considerable melanoma affinity (18, (20) (21) (22) , with 99m Tc-1 displaying an in vivo melanoma uptake of 7.6% ID/g (melanoma/ nontarget tissue = 9.5) at 1 hour postinjection in the s.c. C57BL6/B16F0 mouse model (20) . This in vivo melanoma uptake of 99m Tc-1 is comparable with that of the radioiodinated IMBA and BZA molecules, which have 6% to 8% ID/g in the same s.c. mouse model (13) .
In vitro cell uptake studies. B16F10 cell uptake studies over a 1-hour incubation period at 37jC (Fig. 3A) show rapid uptake of 99m Tc-1, with a 30% maximum being reached within 20 minutes. Because L-tyrosine is the main substrate in the synthesis of melanin via the oxidative enzyme tyrosinase, melanin synthesis/content is enhanced by growing B16F10 cells in DMEM medium supplemented with additional L-tyrosine (2.0 mmol/L). There is a significant darkening of the cells/medium compared with control cells cultured in DMEM alone. These tyrosine-stimulated cells have a rapid and significantly enhanced cellular accumulation of the 99m Tc complex at 37jC, such that within 5 minutes of incubation they display a 70% uptake of 99m Tc-1, which reaches a maximum of 78% in 60 minutes. To distinguish an active accumulation component from passive diffusion, simultaneous experiments were done at 4jC (Fig. 3B) . Under these conditions a significant reduction in cellular uptake is observed in the cells cultured in DMEM alone, with a maximum of only 8% observed over a 60-minute period, indicating that a significant fraction of the cellular uptake of 99m Tc-1 by B16F10 melanoma cells is due to active, temperature-dependent processes. At 4jC, the cellular accumulation in tyrosine-stimulated cells is reduced from a maximum of 78% to 50%; moreover, the uptake is higher than that observed for control cells at 37jC, suggesting that the uptake and accumulation of the 99m Tc-1 complex is related to the melanin synthesis/content of the cells, a phenomenon also observed with the radioiodinated benzamides (10, 22, 27) .
NBdNJ added to the growth medium of melanoma cells produces functionally inactive tyrosinase, a result of inhibition of correct N -glycan processing, and thereby reduces melanin synthesis/content within intact melanoma cells. Despite this incomplete glycan processing, the enzyme is transported to the melanosome; however, it lacks catalytic activity, in effect, generating amelanotic B16F10 cells that appear pale in color and contain little or no melanin compared with normal control cells (18) . Cellular uptake studies in these NBdNJ-treated cells show a dramatic decrease in accumulation of 99m Tc-1, with a maximum uptake of 6% at 37jC throughout the 1-hour incubation period (Fig. 3A) . Taken together, these in vitro cell uptake data indicate the effect of modulating the melanin synthesis/content on the accumulation of 99m Tc-1 by intact melanoma cells and suggest that mechanistically the accumulation of 99m Tc-1 is related to their melanin synthesis/content.
In vivo biodistribution of [ 99m TcOAADT]-(CH 2 ) 2 -NEt 2 in B16F10 metastatic melanoma models. In vivo distribution of 99m Tc-1 was examined in the s.c. mouse model bearing metastatic B16F10 tumors. The biodistribution values in Table 1 show high in vivo tumor uptake of 99m Tc-1 at 2 hours after its administration. This tumor uptake is similar to that observed previously (20) and is also comparable with that obtained with the iodobenzamides in the B16F0 tumor model (13) . The biodistribution data over an extended 6-hour period also indicate that tumor uptake of 99m Tc-1 remains high whereas a relatively faster washout from normal organs results in increasing tumor/ nontumor ratios (Table 1) .
For comparison of the in vivo melanoma uptake of 99m Tc-1 with that of other small-molecule PET imaging probes such as 2-[ As the foremost concern in the evaluation of patients diagnosed with metastatic melanoma is the detection of the presence and extent of metastasis at distant sites, 99m Tc-1 was also assessed in mice that received an i.v. inoculation of B16F10 melanoma cells, resulting in the formation of metastatic melanoma lesions in the lungs. When mice are evaluated 11 days after receiving 4 Â 10 5 B16F10 cells i.v., they have a significantly higher lung uptake of 99m Tc-1 2 hours postadministration of the radiopharmaceutical than normal mice (4.55 F 0.83% ID/g versus 2.13 F 0.20% ID/g, respectively, P < 0.05; Table 2 ). This difference in lung uptake increases further at 3 hours postinjection of the compound, with the uptake of 11-day tumor-bearing mice 3.44 F 0.94% ID/g and that of normal mice 0.89 F 0.26% ID/g, indicating a relatively faster washout of 99m Tc-1 from normal lung tissue compared with lungs bearing metastatic melanoma lesions. When the time interval following tumor cell inoculation is prolonged to 14 days to allow further growth of the metastatic lesions, the accumulation of 99m Tc-1 in the lungs increases to 6.12 F 0.81% ID/g and 7.74 F 1.34% ID/g at 2 and 3 hours postadministration, respectively. Moreover, at 17 days post tumor cell injection, the uptake of 99m Tc-1 in the lungs reaches a value of 10.84 F 2.03% ID/g at 2 hours postadministration. This accumulation of 99m Tc-1 as a function of the growth of the metastatic pulmonary melanoma lesions over time is illustrated in Fig. 5A .
The uptake of 99m Tc-1 was also examined in a group of mice that received varying doses of B16F10 tumor cells 14 days before the assessment. The uptake of 99m Tc-1 in the lungs of these tumorbearing mice has a positive correlation with the number of tumor cells administered, such that mice receiving 2 Â 10 5 , 4 Â 10 5 , and 8 Â 10 5 B16F10 cells have lung uptake of 2.83 F 0.21% ID/g, 3.63 F 1.07% ID/g, and 4.92 F 1.61% ID/g, respectively, compared with 2.13 F 0.20% ID/g observed in the lungs of normal mice (Table 3 ; Fig. 5B ). Taken together, these in vivo experiments illustrate the potential use of 99m Tc-1 as an in vivo probe to assess both temporal growth and extent of metastatic tumor burden in the lungs.
Histology. Evaluation of numerous histologic sections of the lung, liver, spleen, and brain of animals bearing s.c. B16F10 tumors does not indicate any metastatic lesions in these organs. However, as previously shown (19) (20) (21) 24) , excised lungs from mice that received i.v. inoculations of B16F10 melanoma cells have distinct small black melanoma colonies, which increase both in number and in size with increasing dose of the tumor inoculum. Paraffinembedded sections from metastatic tumor-bearing lungs of mice receiving i.v. inoculation of 2 Â 10 5 , 4 Â 10 5 , and 8 Â 10 5 B16F10 melanoma cells 14 days before evaluation are shown in Fig. 6 . The administration of 2 Â 10 5 tumor cells results in the formation of a significant number of small distinct metastatic lesions with most of these extravasated near blood vessels (Fig. 6A and B) . Increasing the tumor dose to 4 Â 10 5 and 8 Â 10 5 cells causes a significant increase in both the number and size of the metastatic lesions ( Fig. 6C and D) . As previously observed (24) (25) (26) 30) , the metastatic lesions not only extravasate and grow near blood vessels but also grow near and at the lung surface; this is quite pronounced in the 14-day lung tissue when 8 Â 10 5 cells have been administered (Fig. 6D ).
An increase in both the number and size of metastatic melanoma lesions also occurs in the group where the time post tumor cell injection (4 Â 10 5 cells) is prolonged from 11 to 17 days. This was visually apparent at the time of dissection (Fig. 7) . After biodistribution studies with this group of mice at 2 hours postadministration of 99m Tc-1 (Table 2) , the excised lung tissue was photographed and subjected to ex vivo radiophosphor imaging. The distinct and specific localization of 99m Tc-1 by the melanotic lesions as observed in the radiophosphor images (Fig. 7) is underscored by the intensity and specificity of the accumulated activity in the individual tumor lesions. Also apparent in the correlative examination of the radiophosphor images with the digital images of the lung tissue displayed in Fig. 7 is the relationship of the level of accumulation of 99m Tc-1 to the degree of melanin in the individual melanotic lesions. Histologic examination of lung sections does not reveal any infiltrating inflammatory cells at or near the metastatic lesions. In conjunction with the specific uptake of 99m Tc-1 observed in the radiophosphor images, this observation emphasizes that the accumulation is specifically localized in the tumor cells.
Whereas examination of this group of mice (i.v. tumor inoculation) does not show any distant metastasis in the liver and spleen, the sections of the brain display small but noticeable infarcted areas. A closer and more detailed examination of the brain sections adjoining the infarcted regions reveals blockade in the blood vessels by small but distinct tumor metastases (Fig. 5E  and F) . Further detailed examination of the brain sections shows no metastatic tumor growth within the brain tissue, and small tumor metastases confined to the blood vessels supplying the neighboring infarcted areas. The corresponding in vivo brain uptake of 99m Tc-1 in the biodistribution studies of these mice indicates a very small increase in uptake compared with normal mice (Table 3 ). This increase may be relatively small due to a number of factors: (a) the whole brain is excised and measured and the number and size of such metastases in the brain vasculature are very small; (b) a reduction in blood flow due to blockade of the vessels by the metastases produces decreased delivery and extraction of 99m Tc-1 in the relatively small tumor metastases; and (c) the presence of small infarcted areas caused by the blockade may also bring about decreased brain uptake of 99m Tc-1. A more detailed study using this model will be required to derive any conclusions with respect to brain uptake of 99m Tc-1 and melanoma metastases within the brain vasculature.
99m Tc-1, a small, neutral technetium complex, displays high melanoma uptake in both s.c. and pulmonary metastatic melanomas. The use of a more realistic model for evaluating metastatic melanoma-targeting agents shows that 99m Tc-1 not only has high and specific uptake by melanoma metastases in the lungs but also can potentially provide a means to assess noninvasively both temporal growth and extent of metastatic tumor burden in vivo.
